Hepatocarcinoma
19
6
7
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.3%
1 terminated out of 19 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (19)
Evaluation of Skin Tests in Biotherapy Allergies
Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches
Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
HCC Innervation Assessment
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Study on the Quality of Life (QoL) After Liver Surgery
Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib
HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas
11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE
Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma
Robotic Endomicroscopy to Better Define Resection Strategies Applied to Hepatic Surgery
Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma